Researchers 'turn off' most notorious cancer-causing protein

December 2, 2015
Researchers ‘turn off’ most notorious cancer-causing protein
Mouse tumour

It's known as the most common cancer-causing protein, directly responsible for 30 per cent of all cancers and indirectly involved in virtually all cancers. For over 30 years, scientists have failed to successfully target it, but now researchers from U of T can turn this protein off with an experimental drug.

"For several decades, scientists have tried to turn off a protein called Ras," said Michael Ohh, a professor in the Faculty of Medicine's Department of Laboratory Medicine and Pathobiology. "But despite their efforts, we ultimately haven't seen much progress. In fact, it's been coined the 'undruggable' protein."

Normally, Ras promotes cell growth, but it can also cause when mutated or deregulated. As a result, this protein is a key player in many forms of and is mutated in over 90 per cent of pancreatic tumours—one of the deadliest forms of cancer.

The discovered that another protein, called SHP2, turns Ras off. "Our lab is known for another area of cancer biology. But on the request from a colleague, we entered the Ras field about five years ago to study mutations in a rare form of childhood leukemia," said Ohh. "We were surprised to find that nobody had identified SHP2 as a switch that regulates Ras that it could be targeted."

Working with researchers from Indiana University and Toronto's University Health Network, the team tested a SHP2 inhibitor on mice with glioblastoma, the most common and aggressive type of brain cancer. Remarkably, the inhibitor reduced these tumours by over 80 per cent.

"The inhibitors' results were incredible—we were shocked," said Ohh. "Nothing has had the same effect."

The researchers' findings were recently published in Nature Communications.

Dr. Yoshihito Kano (left) and Professor Michael Ohh

Next, the team will work with a cancer surgeon at the University of North Carolina to treat mice that have human pancreatic tumours. If the SHP2 inhibitor is effective, the

researchers will use this evidence to support future human clinical trials.

"In addition to being a researcher, I'm also a gastroenterologist and I see a lot of patients with ," said Yoshihito Kano, co-author of the publication along with Severa Bunda, the primary author. "These patients usually die within one year, even with chemotherapy, so this drug could potentially change my patients' lives."

While their research is still in its early stages, Ohh and his team hope that their discovery will open up new perspectives in the field and potentially change cancer treatment.

"By better understanding how this cancer-causing works, we hope to target it much more precisely than before," said Ohh. "At the end of the day, we want other researchers to build on our fundamental discovery, providing more options for patients."

Explore further: Mouse study suggests genomic screening before cancer treatment may prevent anemia

More information: Severa Bunda et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis, Nature Communications (2015). DOI: 10.1038/ncomms9859

Related Stories

Mouse study suggests genomic screening before cancer treatment may prevent anemia

October 13, 2015
Many types of leukemia are caused by loss of enzymes such as Pten, which normally keeps cell growth in check, or conversely, the over-activation of enzymes that normally enhance cell proliferation, such as Shp2. Some anti-leukemia ...

Bacterial sepsis protein may inhibit cancer cell growth

June 8, 2015
A toxin secreted by Vibrio vulnificus, a water and food-borne bacteria that can cause rapidly lethal infections in persons with liver disease, has potential to prevent the growth of tumors, according to a new study by Northwestern ...

Combining the old and new to kill cancer cells

March 23, 2015
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit Kong Cheong, from ...

Scientists uncover potential drug to tackle 'undruggable' fault in third of cancers

November 4, 2014
Scientists have found a possible way to halt one of the most common faults in many types of cancer, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today.

A newly discovered tumor suppressor gene affects melanoma survival

November 2, 2015
Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that appeared last week in Nature Genetics, a Weizmann Institute of Science team has now ...

Blocking 'lock and key' site of lung cancer proteins could lead to new treatments

November 12, 2013
A Cancer Research UK study reveals that stopping two essential lung cancer proteins from joining together at their 'lock and key' site could lead to new treatments for the disease. The research is published in the journal ...

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

betterexists
1 / 5 (1) Dec 02, 2015
Now, New Major Pathway to No Cancer Humans Opens up!
Just Don't Return back; NEVER!
big_hairy_jimbo
5 / 5 (2) Dec 02, 2015
Incredible. This should be fast tracked for Humans with Pancreatic and Brain Cancer. If your prognosis is poor, what do you have to lose by being involved in a trial. I know I would certainly sign ALL consent forms to be a guinea pig, should I be given a cancer death sentence.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.